Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, SANGAMO THERAPEUTICS, INC. reported revenue of $40M, down 31.6% year over year. Operating margin was -306.5% and net margin -310.8%, on a free-cash-flow margin of -246.0% with capital expenditure at 0.3% of revenue. Every figure is computed directly from SGMOQ's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $40M | -306.5% | -310.8% |
| FY2024 | $58M | -179.9% | -169.4% |
| FY2023 | $176M | -155.5% | -146.3% |
| FY2022 | $111M | -180.8% | -172.8% |
| FY2021 | $111M | -165.6% | -161.1% |
How does SGMOQ compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.